11 results
8-K
EX-99.1
nasdhhmcd86
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
DEF 14A
2n25x6
29 Apr 22
Definitive proxy
7:01am
10-K
jm0vwk4e2c
14 Mar 22
Annual report
7:04am
S-1
EX-10.3
hhjwgkx
28 May 21
IPO registration
4:04pm
S-1
EX-10.17
d1cmt7v
28 May 21
IPO registration
4:04pm
DRS
EX-10.3
3wbpptt4f tlazcmp1kn
16 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next